Erectile Dysfunction in Pelvic Cancer Survivors and Current Management Options.
Jose BernalKrishnan VenkatesanFrancisco E MartinsPublished in: Journal of clinical medicine (2023)
Pelvic malignancies, including prostate, rectal, and bladder cancers, are among the most frequent malignancies found in the male population. These issues are most effectively and commonly treated with radiotherapy and/or surgery. However, these treatments can cause collateral damage, resulting in significant impacts on quality of life, with erectile dysfunction being one of the most frequent postoperative complications. Currently, there are several treatment options for erectile dysfunction, including oral phosphodiesterase type 5 inhibitors, vacuum erection devices, intracorporeal injections, and penile prosthesis. The latter has shown to be an effective and safe technique, with results comparable to those obtained by patients without pelvic surgery or radiotherapy. The results of early penile rehabilitation programs are promising and they have been incorporated into a greater proportion of treatment plans more recently, with varying degrees of success. In this narrative review, we summarize the literature on erectile dysfunction after pelvic cancer treatments and its management.
Keyphrases
- robot assisted
- minimally invasive
- rectal cancer
- locally advanced
- early stage
- coronary artery bypass
- end stage renal disease
- prostate cancer
- ejection fraction
- newly diagnosed
- radiation therapy
- young adults
- systematic review
- prognostic factors
- chronic kidney disease
- spinal cord injury
- public health
- childhood cancer
- radical prostatectomy
- papillary thyroid
- health insurance
- acute coronary syndrome
- oxidative stress
- ultrasound guided
- combination therapy
- squamous cell carcinoma
- patient reported outcomes
- squamous cell
- benign prostatic hyperplasia